Novartis Healthcare Private Limited(NHPL) announced today the launch of Sequadra® Inhaler (indacaterol/glycopyrronium)110mcg/50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, indacaterol maleate, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium bromide, a long-acting anticholinergic (LAMA), for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
“NHPLis working hard to optimize this important treatment to Indian patients in a timely way”, said Jawed Zia, Country President, Novartis India. “Once daily indacaterol/glycopyrroniumcombination reduces risk of annual rate of exacerbations by 31% compared to the current standard of care(twice-daily salmeterol+ fluticasone* combination) in patients with moderate-to-severe chronic obstructive pulmonary disease”.
Addressing the media, Prof ClausVogelmeier, Professor of Medicine and Head of Pulmonary Division, Marburg University Hospital, Germany said, “Indacaterol/Glycopyrroniumcombination will offer these patients a much greater improvement in lung function and health related quality of life. This new therapy will change the management of COPD to the benefit of patients”.
This was reinforced by DrPrasanna Kumar Thomas, Consultant Chest Physician Apollo Hospital & Fortis Malar Hospitals, Chennai, , who stated, “Indacaterol/Glycopyrronium is a unique once daily dual bronchodilator (LABA+LAMA) combination, which has published data on efficacy and safety in COPD patients”.
Indacaterol/glycopyrronium combination was developed for the treatment of COPD for patients in whom treatment with a single long acting bronchodilator (LABA or LAMA) does not provide an adequate control of respiratory symptoms.Indacaterol/glycopyrronium combination has demonstrated a statistically significant improvement in lung function at 2 hours post-dose at Week 26.